AIDS prevention pill study halted; no benefit seen
I am not sure we are quite at a ‘never mind’ point just yet, but it’s definitely time to break down these two studies and find out where the difference lies. We’ll have to wait and see how the two other studies that the article mentions turn out.
Great, ERV… Now you get to explain how this fits into the conspiratorial view that Big Pharma is in control of the world and is coercing people to take its useless toxic medz that actually cause teh AIDZ!
But the articles on this drug seem to indicate that it has a positive effect on preventing AIDS in men.
‘However, women taking it were more likely to become pregnant than those on dummy pills. “That’s both a surprising finding and one that we can’t readily explain”‘
How about “women can tell treatment from placebo, and women in the treatment group use condoms less”?
Ben – or, more plausibly than people being able to tell the difference between experimental and placebo pills, that there’s an off-target interaction between Truvada and female sex hormones.
This might render birth control inert (as well as the anti-HIV drug), thus explaining higher incidence of pregnancy and higher HIV infection rate in the experimental group, as well as the presence of a more desirable outcome in gay men.
sorry, that should say, “thus explaining higher incidence of pregnancy and comparable HIV infection rate in the experimental group”
Fair enough. I guess I was just assuming we would already know if Truvada mucked with contraceptives.
The site is currently under maintenance. New comments have been disabled during this time, please check back soon.
This past weekend I hung out at a brand-spanking new con, the Atlanta SciFi and Fantasy…
A paper was recently brought to my attention via a Creationist. It was the usual ‘HAHAHA!…
Ive mentioned this technology on ERV before:
Saving the American Chestnut tree from extinction with GMOs
New, weird, out-of-left-field, ideas– we need them to stop HIV.
This one makes sense, in retrospect, but…
Five kids in the first trial.
Now thirty (ultimately 39):
Chimeric Antigen Receptor T Cells for Sustained…